Department of Gastroenterology and Hepatology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Av. Vasco de Quiroga 15, colonia Belisario Domínguez Sección XVI, Tlalpan, 14080 Mexico City, Mexico.
Department of Genetics, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101519. doi: 10.1016/j.clinre.2020.07.024. Epub 2021 Feb 23.
Alpha-1 antitrypsin deficiency (AATD) is a risk factor for liver disease. PASD-positive inclusions have been found unexpectedly in approximately 10% of liver explants in patients with no previous diagnosis of AATD, particularly, in patients with non-alcoholic steatohepatitis (NASH), supporting a synergistic mechanism of liver injury between AATD and environmental factors. We aimed to determine the clinical characteristics of mestizo patients in which AATD was diagnosed before or after liver transplantation.
Liver explants of patients with cryptogenic, alcoholic, and NAFLD/NASH cirrhosis undergoing orthotopic liver transplantation (OLT) were included. Liver histopathology was assessed by two expert pathologists. Hematoxylin and eosin staining, PASD staining, and confirmatory AAT immunohistochemistry were performed. In explants with positive histopathology, genotyping for SERPINA1 was performed.
A total of 180 liver transplants were performed during the study period. Of these, 44 patients with cryptogenic cirrhosis, NASH, and alcoholic cirrhosis were included. Of these patients, two liver explants (4.5%) had PASD-positive inclusions stain and confirmatory immunochemistry. During the period evaluated, another two patients with a diagnosis of AATD before the OLT were also included. The four patients had overweight or obesity, three had type 2 diabetes mellitus, and two developed liver steatosis after the OLT.
AATD was found to be an infrequent finding in patients with cryptogenic, NASH/NAFLD, and alcoholic cirrhosis in our population. However, it is important to consider this entity as it may represent an additional factor in the appearance and progression of liver fibrosis in patients with metabolic syndrome.
α-1 抗胰蛋白酶缺乏症(AATD)是肝脏疾病的一个风险因素。在没有先前 AATD 诊断的患者的肝移植中,约有 10%的肝组织中意外地发现 PASD 阳性包涵体,尤其是在非酒精性脂肪性肝炎(NASH)患者中,这支持 AATD 和环境因素之间协同作用的肝损伤机制。我们旨在确定在肝移植前或后被诊断为 AATD 的混血患者的临床特征。
纳入接受原位肝移植(OLT)的隐源性、酒精性和非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)肝硬化患者的肝移植标本。由两名专家病理学家评估肝组织病理学。进行苏木精和伊红染色、 PASD 染色和确认的 AAT 免疫组织化学染色。在组织病理学阳性的标本中,进行 SERPINA1 基因分型。
在研究期间共进行了 180 例肝移植。其中,44 例患者患有隐源性肝硬化、NASH 和酒精性肝硬化。在这些患者中,有 2 例肝移植标本(4.5%) PASD 阳性包涵体染色和确认免疫化学染色阳性。在评估期间,还纳入了另外 2 例在 OLT 前被诊断为 AATD 的患者。这 4 例患者均超重或肥胖,3 例患有 2 型糖尿病,2 例在 OLT 后发生肝脂肪变性。
在我们的人群中,AATD 在隐源性、NASH/NAFLD 和酒精性肝硬化患者中发现率较低。然而,考虑到该实体可能是代谢综合征患者肝纤维化出现和进展的另一个因素,这一点很重要。